|Spatial genomic heterogeneity within localized, multifocal prostate cancer|
PC Boutros, M Fraser, NJ Harding, R De Borja, D Trudel, E Lalonde, ...
Nature genetics 47 (7), 736-745, 2015
|Genomic hallmarks of localized, non-indolent prostate cancer|
M Fraser, VY Sabelnykova, TN Yamaguchi, LE Heisler, J Livingstone, ...
Nature 541 (7637), 359-364, 2017
|Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study|
E Lalonde, AS Ishkanian, J Sykes, M Fraser, H Ross-Adams, N Erho, ...
The lancet oncology 15 (13), 1521-1532, 2014
|An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report|
DE Spratt, WH Beeler, FY de Moraes, LD Rhines, JJ Gemmete, ...
The Lancet Oncology 18 (12), e720-e730, 2017
|A prostate cancer “nimbosus”: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies|
MLK Chua, W Lo, M Pintilie, J Murgic, E Lalonde, V Bhandari, ...
European urology 72 (5), 665-674, 2017
|Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer|
M Fraser, A Berlin, RG Bristow, T Van der Kwast
Urologic Oncology: Seminars and Original Investigations 33 (2), 85-94, 2015
|ONECUT2 is a driver of neuroendocrine prostate cancer|
H Guo, X Ci, M Ahmed, JT Hua, F Soares, D Lin, L Puca, A Vosoughi, ...
Nature communications 10 (1), 1-13, 2019
|Prognostic role of Ki-67 score in localized prostate cancer: a systematic review and meta-analysis|
A Berlin, JF Castro-Mesta, L Rodriguez-Romo, D Hernandez-Barajas, ...
Urologic Oncology: Seminars and Original Investigations 35 (8), 499-506, 2017
|An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy|
RG Bristow, A Berlin, A Dal Pra
The British journal of radiology 87 (1035), 20130753, 2014
|Translating a prognostic DNA genomic classifier into the clinic: retrospective validation in 563 localized prostate tumors|
E Lalonde, R Alkallas, MLK Chua, M Fraser, S Haider, A Meng, J Zheng, ...
European urology 72 (1), 22-31, 2017
|Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression|
S Chen, G Zhu, Y Yang, F Wang, YT Xiao, N Zhang, X Bian, Y Zhu, Y Yu, ...
Nature Cell Biology 23 (1), 87-98, 2021
|Challenges and opportunities in primary CNS lymphoma: a systematic review|
MN Kerbauy, FY Moraes, BH Lok, J Ma, LN Kerbauy, DE Spratt, ...
Radiotherapy and Oncology 122 (3), 352-361, 2017
|Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial|
NM Richard, LJ Bernstein, WP Mason, N Laperriere, C Maurice, BA Millar, ...
Journal of neuro-oncology 142 (3), 565-575, 2019
|NBN gain is predictive for adverse outcome following image-guided radiotherapy for localized prostate cancer|
A Berlin, E Lalonde, J Sykes, G Zafarana, KC Chu, VR Ramnarine, ...
Oncotarget 5 (22), 11081, 2014
|Lessons learned using an MRI-only workflow during high-dose-rate brachytherapy for prostate cancer|
J Murgic, P Chung, A Berlin, A Bayley, P Warde, C Catton, A Simeonov, ...
Brachytherapy 15 (2), 147-155, 2016
|Genomic classifier for guiding treatment of intermediate-risk prostate cancers to dose-escalated image guided radiation therapy without hormone therapy|
A Berlin, J Murgic, A Hosni, M Pintilie, A Salcedo, M Fraser, S Kamel-Reid, ...
International Journal of Radiation Oncology* Biology* Physics 103 (1), 84-91, 2019
|Mismatch repair gene expression and genetic instability in testicular germ cell tumor|
A Velasco, E Riquelme, M Schultz, II Wistuba, L Villarroel, J Pizarro, ...
Cancer biology & therapy 3 (10), 977-982, 2004
|Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer|
H Lieng, M Pintilie, A Bayley, A Berlin, R Bristow, P Chung, ...
Radiotherapy and Oncology 122 (1), 93-98, 2017
|A prospective study of 18F-DCFPyL PSMA PET/CT restaging in recurrent prostate cancer following primary external beam radiotherapy or brachytherapy|
W Liu, K Zukotynski, L Emmett, HT Chung, P Chung, R Wolfson, ...
International Journal of Radiation Oncology* Biology* Physics 106 (3), 546-555, 2020
|A systematic review of the evidence for the decipher genomic classifier in prostate cancer|
NK Jairath, A Dal Pra, R Vince Jr, RT Dess, WC Jackson, JJ Tosoian, ...
European urology 79 (3), 374-383, 2021